The Queen's University of Belfast

Almac Group Limited

David Hirst

Tianbao Chen

Martin O'Rourke

Brian Walker

Christopher Shaw

Tracy Robson

Pingfan Rao

Hayley McKeen

Christopher Byrne

Chris Shaw

Hayley Mckeen

Disclosed are methods that employ FKBPL as a marker for a subject's sensitivity to endocrine therapies in the treatment of cancers, and as a predictive marker of cancer progression and disease free survival in relation to hormone responsive cancers.

Assay methods for the determination of FKBPL expression level in the context of breast cancer

Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth muscle. It may be used treatment of diseases of the cardiovascular system and in promotion of angiogenesis.

Peptides, compositions and uses thereof

A bradykinin B2-receptor antagonist peptide, kinestatin, isolated from toad () defensive skin secretion, and analogs thereof, is disclosed. The structure of kinestatin is pGlu-Leu/Ile-Pro-Gly-Leu/Ile-Gly-Pro-Leu/Ile-Arg-NH. Also disclosed are kinestatin analogs, prodrugs including the peptides, fusion peptides and multimeric peptides including the peptide sequences, pharmaceutical compositions including kinestatin and analogs thereof, prodrugs, fusion and multimeric peptides thereof, nucleic acids encoding kinestatin and analogs thereof, and nucleic acids encoding the fusion and multimeric peptides. Kinestatin and analogs thereof (including the prodrugs and multimeric and/or fusion peptides) can be used to treat and/or prevent disorders associated with bradykinin, including cardiovascular disorders, inflammation, asthma, allergic rhinitis, pain, angiogenesis and the like.

[object Object]

Growing community of inventors

Belfast, United Kingdom

David Hirst